[go: up one dir, main page]

SI2875022T1 - Spojine difluorolaktama kot selektivni antagonisti EP4 za uporabo pri zdravljenju z EP4-povzročenih bolezni in stanj - Google Patents

Spojine difluorolaktama kot selektivni antagonisti EP4 za uporabo pri zdravljenju z EP4-povzročenih bolezni in stanj

Info

Publication number
SI2875022T1
SI2875022T1 SI201330477A SI201330477A SI2875022T1 SI 2875022 T1 SI2875022 T1 SI 2875022T1 SI 201330477 A SI201330477 A SI 201330477A SI 201330477 A SI201330477 A SI 201330477A SI 2875022 T1 SI2875022 T1 SI 2875022T1
Authority
SI
Slovenia
Prior art keywords
receptor
treatment
conditions
mediated disease
selective agonists
Prior art date
Application number
SI201330477A
Other languages
English (en)
Inventor
Stephen Douglas Barrett
Fred Lawrence Ciske
Joseph Michael Colombo
Gregory William Endres
Bradlee David Germain
Andriy Kornilov
James Bernard Kramer
Adam Uzieblo
Kirk M. Maxey
Original Assignee
Cayman Chemical Company, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayman Chemical Company, Incorporated filed Critical Cayman Chemical Company, Incorporated
Publication of SI2875022T1 publication Critical patent/SI2875022T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0042—Materials resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/365—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
SI201330477A 2012-07-19 2013-07-19 Spojine difluorolaktama kot selektivni antagonisti EP4 za uporabo pri zdravljenju z EP4-povzročenih bolezni in stanj SI2875022T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261673514P 2012-07-19 2012-07-19
US201361793929P 2013-03-15 2013-03-15
EP13745744.6A EP2875022B1 (en) 2012-07-19 2013-07-19 Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
PCT/US2013/051263 WO2014015247A1 (en) 2012-07-19 2013-07-19 Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions

Publications (1)

Publication Number Publication Date
SI2875022T1 true SI2875022T1 (sl) 2017-04-26

Family

ID=48916211

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330477A SI2875022T1 (sl) 2012-07-19 2013-07-19 Spojine difluorolaktama kot selektivni antagonisti EP4 za uporabo pri zdravljenju z EP4-povzročenih bolezni in stanj

Country Status (20)

Country Link
US (8) US9180116B2 (sl)
EP (4) EP3175852B1 (sl)
JP (3) JP6141430B2 (sl)
KR (2) KR102151578B1 (sl)
CN (4) CN106748951B (sl)
AU (3) AU2013292357C1 (sl)
CA (2) CA2879507A1 (sl)
CY (1) CY1118929T1 (sl)
DK (2) DK3175852T3 (sl)
ES (3) ES2728159T3 (sl)
HR (1) HRP20170045T1 (sl)
HU (2) HUE031885T2 (sl)
IL (3) IL236637A (sl)
LT (1) LT2875022T (sl)
NZ (2) NZ704171A (sl)
PH (1) PH12015500111A1 (sl)
PL (1) PL2875022T3 (sl)
PT (2) PT2875022T (sl)
SI (1) SI2875022T1 (sl)
WO (2) WO2014015246A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2875022T1 (sl) 2012-07-19 2017-04-26 Cayman Chemical Company, Incorporated Spojine difluorolaktama kot selektivni antagonisti EP4 za uporabo pri zdravljenju z EP4-povzročenih bolezni in stanj
EP2970234B1 (en) * 2013-03-15 2018-07-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
HU231033B1 (hu) 2016-03-22 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás 3-as kötést tartalmazó optikailag aktív karbonsavak, karbonsav sók és karbonsav származékok előállítására
CN106699604B (zh) * 2017-01-09 2019-01-01 四川同晟生物医药有限公司 一种沙库比曲及其中间体的制备方法
EP3446661B1 (en) 2017-08-21 2021-12-29 Cook Medical Technologies LLC Braided stent crown geometry and flare

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
ZA747723B (en) * 1974-12-11 1976-11-24 Pfizer 11-desoxy-15-substituted-omega-pentanor prostaglandins
US4154949A (en) 1974-12-11 1979-05-15 Pfizer Inc. 11-Desoxy-15-substituted-ω-pentanor prostaglandins
IT1037126B (it) * 1975-03-14 1979-11-10 Erba Carlo Spa 13.4 deidro ii desossi prosta glandine
DE2517771A1 (de) 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
CA1085859A (en) 1975-06-27 1980-09-16 Wilhelm Bartmann Pyrrolidones and process for their manufacture
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
DE2729960A1 (de) * 1977-06-30 1979-01-18 Schering Ag Neue acetylenprostaglandine und verfahren zu ihrer herstellung
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
GB8329559D0 (en) 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
EP0365678B1 (en) 1987-10-16 1994-01-05 Toray Industries, Inc. 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF
JPH0662599B2 (ja) 1987-10-16 1994-08-17 東レ株式会社 ２，５，６，７―テトラノル―４，８―インタ―ｍ―フェニレンＰＧＩ２誘導体ならびにその製造法および用途
DE3835162A1 (de) * 1988-10-13 1990-04-19 Schering Ag (1s,2s,3r,5r)-2-((3s)-2-halogen-3-hydroxy-1-alken(inyl))-3-trialkylsilyloxy-7,7-(2,2-dimethyl-trimethylendioxy)-bicyclo-(3.3.0)-octan-verbindungen und verfahren zu deren herstellung
US7208179B1 (en) 1990-11-27 2007-04-24 The American National Red Cross Methods for treating disease and forming a supplemented fibrin matrix
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
JP3388867B2 (ja) 1994-03-31 2003-03-24 株式会社東芝 宛名領域検出装置および宛名領域検出方法
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US20020098222A1 (en) 1997-03-13 2002-07-25 John F. Wironen Bone paste
ZA984040B (en) 1997-05-15 1998-11-20 Ono Pharmaceutical Co Benzenesulfonamide compounds
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
TR200201643T2 (tr) 1999-12-22 2002-11-21 Pfizer Products Inc. Osteoporoz tedavisi için EP4 reseptörünü seçici agonistler.
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
JP3984164B2 (ja) * 2000-11-27 2007-10-03 ファイザー・プロダクツ・インク 骨粗鬆症治療用ｅｐ４受容体選択的アゴニスト
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
CN1863768A (zh) * 2001-07-16 2006-11-15 霍夫曼-拉罗奇有限公司 作为ep4受体激动剂的前列腺素类似物
CA2451393C (en) 2001-07-16 2011-01-04 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
ES2254726T3 (es) * 2001-07-16 2006-06-16 F. Hoffmann-La Roche Ag Analogos de prostaglandina como agonistas receptores de ep4.
JP4273407B2 (ja) 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
ATE391503T1 (de) 2001-10-23 2008-04-15 Serono Lab Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren
AU2002346562A1 (en) * 2001-12-03 2003-06-17 Merck & Co., Inc. Method for treating ocular hypertension
AU2002346561B2 (en) 2001-12-03 2006-08-17 Merck & Co., Inc. EP4 receptor agonist, compositions and methods thereof
MXPA04008596A (es) 2002-03-05 2004-12-06 Ono Pharmaceutical Co Compuestos derivados de 8-azaprostaglandina y farmacos que contienen los compuestos como ingrediente activo.
MXPA04005555A (es) 2002-03-18 2005-05-16 Pfizer Prod Inc Procedimientos de tratamiento con agonistas selectivos del receptor ep4.
JP2005526080A (ja) 2002-03-18 2005-09-02 ファイザー・プロダクツ・インク 肝不全、動脈管閉鎖、緑内障又は高眼圧の治療のための選択的ｅｐ４受容体アゴニストの使用
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003103604A2 (en) * 2002-06-01 2003-12-18 Applied Research Systems Ars Holding N.V Gamma lactams as prostaglandin agonists and use thereof
US20050239872A1 (en) 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
JP2006505572A (ja) 2002-10-25 2006-02-16 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体アゴニストとしての２−ピロリドン
JP4582456B2 (ja) 2003-01-21 2010-11-17 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体およびその医薬用途
CA2513652A1 (en) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US7163920B2 (en) 2003-09-30 2007-01-16 Ethicon, Inc. Peptide with osteogenic activity
US20070191319A1 (en) 2003-12-17 2007-08-16 Pfizer Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
WO2006016689A1 (ja) 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
US20080234337A1 (en) 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
US20060039949A1 (en) 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060057184A1 (en) 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US7621963B2 (en) 2005-04-13 2009-11-24 Ebi, Llc Composite bone graft material
KR101465994B1 (ko) 2005-05-27 2014-11-27 로이어 바이오메디칼 인코포레이티드 생체재흡수성 중합체 매트릭스 및 이의 제조방법과 사용방법
DK1933892T3 (da) 2005-09-09 2013-03-25 Agnovos Healthcare Llc Sammensat knoglegrafterstatningscement og artikler fremstillet deraf
KR20060013354A (ko) 2005-12-09 2006-02-09 (주)코리아 본 뱅크 인산칼슘계 시멘트 첨가에 의해 개질된 탈회골 기질의 개발
US20070232660A1 (en) 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2147672A4 (en) 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
NZ583351A (en) * 2007-08-15 2012-05-25 Cytokinetics Inc Modulate smooth muscle myosin and/or non-muscle myosin
MX2010004487A (es) 2007-10-23 2010-05-05 Allergan Inc Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
US20090112332A1 (en) 2007-10-31 2009-04-30 Alexis Paul Shelokov Bone graft and bone graft substitutes with antibiotics for sustained, localized release of antibiotics for reducing postoperative surgical wound infection in spinal and other bone surgery
WO2011127149A1 (en) 2010-04-06 2011-10-13 University Of Utah Research Foundation Controlled release combination biomaterials
US8685432B2 (en) 2008-03-25 2014-04-01 University Of Utah Research Foundation Controlled release tissue graft combination biomaterials
JP6324653B2 (ja) 2008-04-15 2018-05-16 ライフ サイエンス エンタープライジズ インコーポレイテッド リン酸カルシウム配合骨セメントを用いる脊椎骨の最小侵襲治療（ｍｉｔｖ）
US20100021524A1 (en) 2008-07-22 2010-01-28 Osteogenex Inc. Pimethixene derivatives for promoting bone growth
WO2010025135A2 (en) 2008-08-28 2010-03-04 Osteogenex Inc. Trimeprazine and ethopropazine derivatives for promoting bone growth
US9320761B2 (en) 2008-12-18 2016-04-26 Vivex Biomedical, Inc. Bone induction system and methods
WO2011003058A1 (en) 2009-07-03 2011-01-06 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
JP5847830B2 (ja) * 2010-11-10 2016-01-27 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体拮抗薬として有用なラクタム誘導体
AU2011329054B2 (en) 2010-11-15 2015-05-28 Zimmer Orthobiologics, Inc. Bone void fillers
US20120283293A1 (en) 2011-05-06 2012-11-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation
KR20140056250A (ko) 2011-08-02 2014-05-09 오노 야꾸힝 고교 가부시키가이샤 좌심실 확장 기능 개선제
US20170260173A1 (en) 2012-07-19 2017-09-14 Myometrics, Llc Difluorolactam compositions for ep4-mediated osteo related diseases and condtions
SI2875022T1 (sl) 2012-07-19 2017-04-26 Cayman Chemical Company, Incorporated Spojine difluorolaktama kot selektivni antagonisti EP4 za uporabo pri zdravljenju z EP4-povzročenih bolezni in stanj
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
EP2970234B1 (en) * 2013-03-15 2018-07-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
JP6062599B1 (ja) 2015-08-03 2017-01-18 株式会社ｓｉｚｅｂｏｏｋ 携帯情報装置、寸法測定方法、および寸法測定プログラム

Also Published As

Publication number Publication date
US9487478B2 (en) 2016-11-08
CN104640542A (zh) 2015-05-20
WO2014015247A1 (en) 2014-01-23
IL250725A0 (en) 2017-04-30
JP2019163300A (ja) 2019-09-26
CN106748951B (zh) 2020-07-24
CN107802623A (zh) 2018-03-16
EP2874620A1 (en) 2015-05-27
CN107802623B (zh) 2020-10-30
US20170066751A1 (en) 2017-03-09
DK3175852T3 (da) 2019-05-27
NZ704171A (en) 2017-10-27
CN104640542B (zh) 2017-09-22
EP3175852A1 (en) 2017-06-07
JP2015522623A (ja) 2015-08-06
HK1206016A1 (en) 2015-12-31
AU2013292357C1 (en) 2017-05-25
CA2879506A1 (en) 2014-01-23
AU2013292357B2 (en) 2017-02-02
PT2875022T (pt) 2016-12-22
US10556862B2 (en) 2020-02-11
KR20150036652A (ko) 2015-04-07
HUE031885T2 (en) 2017-08-28
US20150175538A1 (en) 2015-06-25
KR102131378B1 (ko) 2020-07-08
EP3176162A1 (en) 2017-06-07
JP6766008B2 (ja) 2020-10-07
CN104583201B (zh) 2016-12-14
EP3175852B1 (en) 2019-03-06
PT3175852T (pt) 2019-06-04
JP2017160237A (ja) 2017-09-14
JP6141430B2 (ja) 2017-06-07
US9701630B2 (en) 2017-07-11
EP2875022B1 (en) 2016-10-12
US20150174099A1 (en) 2015-06-25
NZ704178A (en) 2017-08-25
IL236637A (en) 2016-04-21
IL236636A0 (en) 2015-02-26
US11884624B2 (en) 2024-01-30
LT2875022T (lt) 2017-03-10
EP2875022A1 (en) 2015-05-27
US9180116B2 (en) 2015-11-10
WO2014015246A1 (en) 2014-01-23
KR102151578B1 (ko) 2020-09-03
US11066361B2 (en) 2021-07-20
CN106748951A (zh) 2017-05-31
US20160340306A1 (en) 2016-11-24
IL236636A (en) 2017-03-30
HRP20170045T1 (hr) 2017-03-10
IL250725B (en) 2019-01-31
US20230050318A1 (en) 2023-02-16
EP3176162B1 (en) 2020-05-27
AU2013292357A1 (en) 2015-02-19
PL2875022T3 (pl) 2017-06-30
CY1118929T1 (el) 2018-01-10
CN104583201A (zh) 2015-04-29
US20190092722A1 (en) 2019-03-28
HUE031190T2 (en) 2017-06-28
CA2879506C (en) 2020-10-27
EP2874620B1 (en) 2016-10-12
US9440919B2 (en) 2016-09-13
KR20150036651A (ko) 2015-04-07
DK2875022T3 (en) 2017-01-23
AU2017200044B2 (en) 2018-12-13
ES2728159T3 (es) 2019-10-22
ES2612921T3 (es) 2017-05-19
CA2879507A1 (en) 2014-01-23
AU2017200044A1 (en) 2017-02-02
HK1205937A1 (en) 2015-12-31
US20200207709A1 (en) 2020-07-02
AU2013292356A1 (en) 2015-02-19
US20160024006A1 (en) 2016-01-28
ES2610428T3 (es) 2017-04-27
PH12015500111A1 (en) 2015-03-30
IL236637A0 (en) 2015-02-26
AU2013292356B2 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
IL238400A0 (en) Triazolopyrazines as brd4 inhibitors for use in cancer therapy
IL233674B (en) Preparations and methods for using phorbol esters for stroke treatment
IL236637A0 (en) Difluorolactam compounds as selective ep4 receptor agonists for use in the treatment of ep4-mediated conditions and diseases
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
IL236823A0 (en) Preparations for use in the treatment of bone defects
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
IL250077A0 (en) Lactam compounds as selective agonists for the ep4 receptor for use in the treatment of ep4-mediated diseases and conditions
ZA201403592B (en) Composition for use in the promotion of magnesium absorption and/or magnesium retention
LT2893019T (lt) Sirnr ir jos panaudojimas būduose ir kompozicijose, skirtose akių ligų gydymui ir (arba) prevencijai
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
PT2875026T (pt) Derivados de imidazopiridina utilizados no tratamento da diabetes
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
ZA201408065B (en) Compositions and methods for the treatment of diabetes
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
GB201208770D0 (en) Compounds for use in the treatment of adenovirus infections
GB201107553D0 (en) Composition and methods for the treatment of neuroendocrine and pitutitary tumoars